Infections in patients with chronic lymphocytic leukemia treated with fludarabine

Annals of Internal Medicine

Volumn 129, Issue 7, 1998, Pages 559-566

  Anaissie, Elias J ^a,b   Kontoyiannis, Dimitrios P ^c   O'Brien, Susan ^d   Kantarjian, Hagop ^d   Robertson, Lester ^e   Lerner, Susan ^d   Keating, Michael J ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Savannah Hematology Oncology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; FLUDARABINE; PREDNISOLONE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HELPER CELL; HERPES ZOSTER; HUMAN; INFECTION RISK; LISTERIOSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0032189459     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-7-199810010-00010     Document Type: Review

References (41)

1. Young JL, Percy CL, Asire AJ. Surveillance, Epidemiology, and End Results: Incidence and Mortality Data, 1973-77. Bethesda, MD: National Cancer Institute; 1981:10. NCI monograph 57.
2. Kontoyiannis DP, Anaissie EJ, Bodey GP. Infection in chronic lymphocytic leukemia: a reappraisal. In: Cheson BD, ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York: Marcel Dekker; 1993:399-417.
3. Cheson BD. Recent advances in the treatment of B-cell chronic lymphocytic leukemia. Oncology (Huntingt). 1990;4:71-8.
4. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25.
5. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia [Letter]. N Engl J Med. 1990;323:833-4.
6. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol. 1988;29:152-63.
7. Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992;80:29-36.
8. Puccio CA, Mittelman A, Lichtman SM, Silver RT, Budman DR, Ahmed T, et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol. 1991;9:1562-9.
9. Anaissie EJ, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating MJ. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117: 466-9.
10. Chapel HM, Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol. 1987;4:291-6.
11. Sanders C, Perez EA, Lawrence HJ. Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine [Letter]. Am J Hematol. 1992;39:314-5.
12. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA. Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia [Letter]. Eur J Cancer. 1991;27:671.
13. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol. 1993;4:371-5.
14. Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991;64:120-3.
15. Grever MR, Kopecky HJ, Coltman CA, Files JC, Greenberg BR, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988;30:457-9.
16. Hiddemann W, Rottmann R, Wormann B, Thiel A, Essink M, Ottensmeier C, et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-ll study. Ann Hematol. 1991;63:1-4.
17. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma. 1995;18:485-92.
18. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995;49:135-42.
19. Papajik T, Faber E, Hubacek J, Slezak P, Raida L, Heczko M, et al. [Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy.] Vnitr Lek. 1997;43:25-8.
20. Pillay GS, Wood L, Jacobs P. Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukemia. S Afr Med J. 1996;86:949-51.
21. Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, Lopez-Guillermo A, et al. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse.] Med Clin (Bare). 1996;107:86-9.
22. Angelopoulou MA, Poziopoulous C, Boussiotis VA, Kontopidou F, Pangalis GA. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response. Leuk Lymphoma. 1996;21:321-4.
23. Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J, et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma. 1996;21: 467-72.
24. De Rossi G, Mauro FR, Caruso R, Monarca B, Mandelli F. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica. 1993;78:167-71.
25. Hequet O, de Jaureguiberry JP, Jaubert D, Gisserot O, Muzellec Y, Brisou P. Listeriosis after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther. 1997;39:89-91.
26. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992;10:790-4.
27. Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology study. J Clin Oncol. 1992; 10:28-32.
28. Dimopoulos MA, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49-52.
29. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82:1695-700.
30. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol. 1993;50:292-6.
31. Schilling PJ. Two views of the immunological effects of fludarabine [Letter]. Oncology (Huntingt). 1991;5:12.
32. Boldt DH, Von Hoff DD, Kuhn JG, Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-βD-arabinofuranosyl-2-fluoroadenine-5′monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984;44:4661-6.
33. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431-48.
34. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semm Oncol. 1998;25:98-106.
35. Girmenia C, Mauro FR, Rahimi S. Late listeriosis after fludarabine plus prednisone treatment. Br J Hematol. 1994;87:407-8.
36. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304-15.
37. Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, et al. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia. 1988;2: 157-64.
38. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood. 1995;86:2063-72.
39. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81:2878-84.
40. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1994;12:2471-508.
41. O'Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997;11:1631-5.